Share-based Payment Arrangement, Expense of Century Therapeutics, Inc. from 30 Jun 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
Century Therapeutics, Inc. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 30 Jun 2020 to 30 Sep 2025.
  • Century Therapeutics, Inc. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $891,000, a 73% decline year-over-year.
  • Century Therapeutics, Inc. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $8,199,000, a 40% decline year-over-year.
  • Century Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2024 was $12,688,000, a 13% decline from 2023.
  • Century Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2023 was $14,622,000, a 136951% increase from 2022.
  • Century Therapeutics, Inc. annual Share-based Payment Arrangement, Expense for 2022 was $10,669, a 100% decline from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

Century Therapeutics, Inc. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $8,199,000 $891,000 -$2,427,000 -73% 01 Jul 2025 30 Sep 2025 10-Q 13 Nov 2025 2025 Q3
Q2 2025 $10,626,000 $2,222,000 -$1,281,000 -37% 01 Apr 2025 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $11,907,000 $2,426,000 -$781,000 -24% 01 Jan 2025 31 Mar 2025 10-Q 15 May 2025 2025 Q1
Q4 2024 $12,688,000 $2,660,000 -$902,000 -25% 01 Oct 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
Q3 2024 $13,590,000 $3,318,000 -$660,000 -17% 01 Jul 2024 30 Sep 2024 10-Q 13 Nov 2025 2025 Q3
Q2 2024 $14,250,000 $3,503,000 +$218,000 +6.6% 01 Apr 2024 30 Jun 2024 10-Q 14 Aug 2025 2025 Q2
Q1 2024 $14,032,000 $3,207,000 -$590,000 -16% 01 Jan 2024 31 Mar 2024 10-Q 15 May 2025 2025 Q1
Q4 2023 $14,622,000 $3,562,000 +$11,488,331 01 Oct 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
Q3 2023 $3,133,669 $3,978,000 +$1,192,000 +43% 01 Jul 2023 30 Sep 2023 10-Q 05 Nov 2024 2024 Q3
Q2 2023 $1,941,669 $3,285,000 +$514,000 +19% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $1,427,669 $3,797,000 +$1,417,000 +60% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q4 2022 $10,669 $7,926,331 01 Oct 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
Q3 2022 $2,786,000 +$1,566,000 +128% 01 Jul 2022 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $2,771,000 +$1,060,000 +62% 01 Apr 2022 30 Jun 2022 10-Q 11 Aug 2022 2022 Q2
Q1 2022 $2,380,000 01 Jan 2022 31 Mar 2022 10-Q 11 May 2023 2023 Q1
Q3 2021 $1,220,000 +$1,076,000 +747% 01 Jul 2021 30 Sep 2021 10-Q 10 Nov 2021 2021 Q3
Q2 2021 $1,711,000 +$1,574,000 +1149% 01 Apr 2021 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q3 2020 $144,000 01 Jul 2020 30 Sep 2020 10-Q 10 Nov 2021 2021 Q3
Q2 2020 $137,000 01 Apr 2020 30 Jun 2020 10-Q 12 Aug 2021 2021 Q2

Century Therapeutics, Inc. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $12,688,000 -$1,934,000 -13% 01 Jan 2024 31 Dec 2024 10-K 19 Mar 2025 2024 FY
2023 $14,622,000 +$14,611,331 +136951% 01 Jan 2023 31 Dec 2023 10-K 19 Mar 2025 2024 FY
2022 $10,669 -$4,651,331 -100% 01 Jan 2022 31 Dec 2022 10-K 14 Mar 2024 2023 FY
2021 $4,662,000 +$3,786,000 +432% 01 Jan 2021 31 Dec 2021 10-K 16 Mar 2023 2022 FY
2020 $876,000 01 Jan 2020 31 Dec 2020 10-K 17 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.